Unternehmen wird geladen
Just reported
Q3 2026 results
From Generate Biomedicines's results release of 12. November 2026; its quarterly report has since been filed.
Revenue
Actual
4,2M $
-56 % y/y
-33 % q/qGuided
—
No guide given
EPS, GAAP
Actual
-0,68 $
Guided
—
No guide given
Operating income, GAAP
Actual
-91,5M $
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Generate Biomedicines is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.47,6B $A+
EXELExelixis, Inc.16,8B $A+
JAZZJazz Pharmaceuticals plc15,5B $A
TECHBIO-Techne Corp11,4B $A+
HALOHalozyme Therapeutics, Inc.11,4B $A+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21. Okt. 2026CBGraded C, now B
MCKMckesson Corporation4. Nov. 2026BAGraded B, now A
CVSCVS Health Corp4. Nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4. Nov. 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28. Okt. 2026CAGraded C, now A
Womit das Unternehmen Geld verdient
- Research collaboration payments100 %
Die Umsatzanteile sind Schätzungen für six months ended June 30, 2026 und keine Zahlen aus einem eingereichten Bericht.
Was es verkauft3
GB-0895
An experimental antibody that blocks thymic stromal lymphopoietin, an immune-system signal. It is being tested in late-stage trials for severe asthma.
GB-4362
An experimental medicine designed to neutralize monomethyl auristatin E, a drug used in some cancer treatments. It has entered human testing.
GB-5267
An experimental cancer treatment using modified chimeric antigen receptor T cells, immune cells altered to recognize and attack cancer. It is being developed with Roswell Park Comprehensive Cancer Center.
Wer es kauft2
- Amgen, which pays for research under a collaboration agreement.
- Novartis, which pays for research under a collaboration agreement.
Worauf es steht, und was es umwerfen könnte
Wovon das Geschäft abhängt
- 1Current revenue depends on research work under agreements with Amgen and Novartis; the company says the work under both agreements is nearing completion.
- 2Clinical research and manufacturing rely in part on outside providers, including contract research organizations and contract development and manufacturing organizations.
- 3Developing and selling medicines depends on clinical trials and regulatory approval.
Was schiefgehen könnte
- 1GB-0895 and the other experimental medicines may not prove safe and effective in clinical trials or receive regulatory approval.
- 2The company has no medicine sales, and its current collaboration revenue depends on research agreements whose work is nearing completion.
- 3The company has ongoing operating losses and expects to need additional funding to continue research and clinical development; it may not obtain that funding on acceptable terms or at all.
Über Generate Biomedicines, Inc.
Generate Biomedicines uses artificial intelligence and laboratory experiments to design and test proteins that could become medicines. Its most advanced candidate is being tested in severe asthma, and it is also developing treatments for other diseases. It has no medicines approved for sale; its current revenue comes from research collaborations with drug companies.
- Hauptsitz
- Cambridge, Massachusetts
- Gegründet
- 2018
- Notiert an
- NASDAQ
- Geschäftsjahresende
- December 31
Gebaut aus den eigenen Einreichungen von Generate Biomedicines, Inc. bei der US-Börsenaufsicht Securities and Exchange Commission (SEC). Die Zahlen sind wie berichtet, die Historie je Aktie auf die heutige Aktienbasis umgerechnet. Dies beschreibt ein Unternehmen — es ist keine Anlageberatung und keine Kauf- oder Verkaufsempfehlung.
